CytomX Therapeutics Inc

NASDAQ:CTMXUnited States

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.

Contact Information

Headquarters

151 Oyster Point Blvd., Suite 400SOUTH SAN FRANCISCO, CA, United States 94080

Phone

650-515-3185

Fax

650-351-0353

Executives

Chairman of the Board, Chief Executive Officer

Sean Mccarthy

Senior Vice President - Finance and Accounting

Chris Ogden

Senior Vice President, Chief Compliance Officer, General Counsel, Secretary

Lloyd Rowland

Senior Vice President, Chief Medical Officer

Yu-Waye Chu

Senior Vice President, Chief Business Officer and Head of Strategy

Jeffrey Landau